Search

Displaying results 2601 - 2610 of 2674 in total
  1. Drug

    Bevirimat

    go.drugbank.com/drugs/DB06581
    Investigational

    It is not currently FDA-approved, but is undergoing clinical trials conducted by the pharmaceutical company Panacos.

  2. Drug

    Etizolam

    go.drugbank.com/drugs/DB09166
    Investigational

    It is not approved for use by FDA in the US; however it remains unscheduled in several states and is legal for research purposes.

  3. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    It was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019.

  4. Target

    DNA-binding transcriptional dual regulator CRP

    go.drugbank.com/bio_entities/BE0002013
    TargetEscherichia coli (strain K12)

    A global transcription regulator, which plays a major role in carbon catabolite repression (CCR) as well as other processes. Binds cyclic AMP (cAMP) which allosterically activates DNA binding (to consensus sequence 5'-AAATGTGATCTAGATCACA...

    Synonyms: cAMP receptor protein
  5. Drug

    Remestemcel-L

    go.drugbank.com/drugs/DB13973
    ApprovedInvestigationalWithdrawn

    [L11022] Remestemcel-L was later approved by the FDA on December 18, 2024.

  6. Target

    Stabilin-1

    go.drugbank.com/bio_entities/BE0010944
    TargetHumans

    Acts as a scavenger receptor for acetylated low density lipoprotein. Binds to both Gram-positive and Gram-negative bacteria and may play a role in defense against bacterial infection.

    Synonyms: Fasciclin, EGF-like, laminin-type EGF-like and link domain-containing scavenger receptor 1
  7. Drug

    Albinterferon Alfa-2B

    go.drugbank.com/drugs/DB05396
    Investigational

    In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug.

  8. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    [A229938] Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012.

  9. Drug

    Lutetium Lu 177 dotatate

    go.drugbank.com/drugs/DB13985
    ApprovedInvestigational

    Lutetium Lu 177 dotatate was approved by the FDA as Lutathera in January 2018 for intravenous injection. … A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with

  10. Target

    Sodium-dependent phosphate transporter 2

    go.drugbank.com/bio_entities/BE0008680
    TransporterHumans

    Sodium-phosphate symporter which preferentially transports the monovalent form of phosphate with a stoichiometry of two sodium ions per phosphate ion (PubMed:12205090, PubMed:15955065, PubMed:16790504, PubMed:17494632, PubMed:22327515, P...

    Synonyms: Gibbon ape leukemia virus receptor 2Function: signaling receptor activity